Clinical Trials, Therapeutics, FDA Corey Hubbard Clinical Trials, Therapeutics, FDA Corey Hubbard

PTSD Breakthrough: FDA Designates TSND-201 for Rapid Relief

The recent announcement by Transcend Therapeutics regarding the US Food and Drug Administration (FDA) granting breakthrough therapy designation to their drug, TSND-201, for the treatment of Post-Traumatic Stress Disorder (PTSD) marks a significant moment for the millions of Americans living with this debilitating condition. This designation is a beacon of hope, promising to accelerate the development and review

Read More